Cargando…

The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis

BACKGROUND: Combined therapy with alendronate and calcitriol may have additive effects on bone density. An observational study was performed to evaluate the efficacy and safety of Maxmarvil, a combinative agent of alendronate (5 mg) and calcitriol (0.5 µg), and to identify factors associated with ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suh, Hee-Won, Kim, Hyun-Ok, Kim, Young Sik, Sunwoo, Sung, Lee, Jung Ah, Lee, Hye-Ree, Kim, Byungsung, Kim, Dae Hyun, Choi, Youn Seon, Cheong, Yoo Seock, Yum, Keunsang, Yang, Yun Jun, Yu, Byung-Yeon, Cho, Chung Hwan, Park, Sat-Byul, Shin, Dong Hyeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Family Medicine 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526717/ https://www.ncbi.nlm.nih.gov/pubmed/23267420 http://dx.doi.org/10.4082/kjfm.2012.33.6.346

Ejemplares similares

Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with Osteoporosis
por: Yoo, Jun-Il, et al.
Publicado: (2017)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Factors of Compliance in Patients with Hypercholesterolemia Using Rosuvastatin in Primary Care
por: Kim, Hye Young, et al.
Publicado: (2012)

Effect of combined treatment with alendronate and calcitriol on femoral neck strength in osteopenic rats
por: Nakamura, Yoshinari, et al.
Publicado: (2008)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
por: Kim, Hyun Ok, et al.
Publicado: (2013)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Comparative Study on Hysteroscopic and Histologic Examinations of the Endometrium in Postmenopausal Women Taking Tamoxifen
por: Jung, Hyuk, et al.
Publicado: (2018)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Alendronate sodium/vitamin D(3) combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
por: Zhang, Z. L., et al.
Publicado: (2015)

Association between Serum Uric Acid and Oxidative Stress in Korean Adults
por: Ok, Eun Jeong, et al.
Publicado: (2018)

Erratum to: Alendronate sodium/vitamin D(3) combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension
por: Zhang, Z. L., et al.
Publicado: (2015)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
por: Catalano, Antonino, et al.
Publicado: (2021)

The Association between Urine Albumin to Creatinine Ratio and Osteoporosis in Postmenopausal Women with Type 2 Diabetes
por: Lee, Ye Yeon, et al.
Publicado: (2016)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
por: Calvo-Gallego, José L., et al.
Publicado: (2022)

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
por: Villagómez Vega, Alejandra, et al.
Publicado: (2023)

Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
por: Yu, Jongwook, et al.
Publicado: (2022)

The Relationship between Prevalence of Osteoporosis and Proportion of Daily Protein Intake
por: Kim, Junga, et al.
Publicado: (2013)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡
por: Xue, Fei, et al.
Publicado: (2013)

Clinical Efficacy and Safety Evaluation of Calcitriol Combined with Bisphosphonates in the Therapy of Postmenopausal Osteoporosis: Based on a Retrospective Cohort Study
por: Jing, Weibing, et al.
Publicado: (2022)

Sequential dual-drug delivery of BMP-2 and alendronate from hydroxyapatite-collagen scaffolds for enhanced bone regeneration
por: Lee, Dongtak, et al.
Publicado: (2021)

The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women
por: Mobini, Maryam, et al.
Publicado: (2016)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Deep learning visual field global index prediction with optical coherence tomography parameters in glaucoma patients
por: Kim, Dongbock, et al.
Publicado: (2023)

Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia
por: Oommen, Tiffany T., et al.
Publicado: (2023)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Retracted: Clinical Efficacy and Safety Evaluation of Calcitriol Combined with Bisphosphonates in the Therapy of Postmenopausal Osteoporosis: Based on a Retrospective Cohort Study
por: International, BioMed Research
Publicado: (2023)

Enhanced osteogenic differentiation of alendronate-conjugated nanodiamonds for potential osteoporosis treatment
por: Ahn, Guk Young, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0sv0mpcd5cmhlpmqbupk5k3gp5